Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Acute pyelonephritis (APN) corresponds to infections of the renal parenchyma. The annual
incidence of these infections is estimated at 4-6 million cases in France, with 60 to 90% of
patients managed in general city medicine. The ceftriaxone, parenteral third-generation
cephalosporin (C3G), occupies an important place in the antibiotic treatment of these
infections: this is the recommended probabilistic treatment, and in some situations the
treatment can be continued in its entirety via a Ceftriaxone monotherapy.
The aim of the last antibiotic plan is to avoid the use of antibiotic therapies with a high
selection capacity (cephalosporins, penicillins, fluoroquinolones, etc.) and thus reduce the
incidence and prolongation over time of the digestive carriage of multi-resistant bacteria .
To date, there have been few studies evaluating the impact of ceftriaxone on the emergence of
multi-resistant bacteria on an individual scale, with rather heterogeneous results (13-86%
C3G resistance).
Thus, before considering randomized studies comparing the ecological impact of different
molecules or therapeutic regimens in the treatment of ANP, it is necessary to have a precise
and rigorous evaluation of the ecological impact of the molecule reference in this
indication.
The investigators propose a study to evaluate the impact on the digestive flora at 1 month of
a ceftriaxone antibiotic therapy (7 days) in the management of acute pyelonephritis in women.